Sinopharm Group Co (OTCPK:SHTDY) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Sinopharm Group Co Forward PE Ratio Related Terms
Sinopharm Group Co Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Forward PE Ratio Chart
Sinopharm Group Co Annual Data
Trend
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
12.44
10.65
7.25
7.17
6.78
5.01
7.12
6.82
Sinopharm Group Co Semi-Annual Data
2018-06
2018-12
2019-06
2019-12
2020-06
2020-12
2021-06
2021-12
2022-06
2022-12
2023-06
2023-12
2024-06
2024-12
2025-06
2025-12
Forward PE Ratio
15.29
12.44
12.11
10.65
8.80
7.25
8.17
7.17
8.35
6.78
8.10
5.01
8.50
7.12
6.71
6.82
SHTDY vs MCK, CAH, COR: Forward PE Ratio Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Forward PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Sinopharm Group Co (SHTDY) has a Forward PE Ratio of 5.68 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sinopharm Group Co and its competitors. According to the industry distribution chart, Sinopharm Group Co ranks #6 out of 51 companies in the Medical Distribution industry, placing it in the top 11.8%.
Is Sinopharm Group Co's Forward PE Ratio too high?
Sinopharm Group Co's current Forward PE Ratio is 5.68. The Medical Distribution industry median Forward PE Ratio is 14.57. Sinopharm Group Co's value of 5.68 is 61% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #6 out of 51 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Forward PE Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #6 out of 51 companies for Forward PE Ratio. This places Sinopharm Group Co in the top 12% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 14.57. Sinopharm Group Co's value of 5.68 is 61% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Distribution company?
The median Forward PE Ratio among Medical Distribution companies is 14.57, based on 51 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Forward PE Ratio of 5.68 is 61% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Forward PE Ratio is 14.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Forward PE Ratio is 5.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.29, compared to a current price of $10.65 — trading 19.9% below its estimated fair value. The current Forward PE Ratio is 5.68 and 61% below the Medical Distribution industry median of 14.57. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Forward PE Ratio is 5.68 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.65 is trading 19.9% below its estimated GF Value™ of $13.29.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
Forward PE Ratio: 5.68
GF Value™: $13.29 vs. price of $10.65 (19.9% below fair value)
Industry Position: 61% below the Medical Distribution median (#6 of 51)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score
Get the complete analysis for SHTDY
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 